Sight Sciences (SGHT) Stock Price, News & Analysis

Company Overview

Sight Sciences, Inc. is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease. Sight Sciences markets its products primarily to ophthalmologists and other eye-care professionals.

Founded in 2010 and headquartered in Menlo Park, California, Sight Sciences serves the United States and select international markets through direct commercial operations and distribution relationships. The company’s products are intended to provide alternatives or complements to traditional pharmaceutical and surgical approaches in glaucoma and dry eye care.

Key Stats

• Today's Range: $9.42 to $10.14
• 50-Day Range: $8.01 to $10.08
• 52-Week Range: $3.38 to $10.31
• Volume: 576,378 shs
• Average Volume: 354,139 shs
• Market Capitalization: $560.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.63
• Consensus Rating: Moderate Buy

Sight Sciences Stock Analysis - MarketRank™

Sight Sciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 493rd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sight Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Sight Sciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Sight Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sight Sciences are expected to grow in the coming year, from ($0.48) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sight Sciences is -19.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sight Sciences is -19.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sight Sciences has a P/B Ratio of 8.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.24% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sight Sciences has recently decreased by 12.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sight Sciences does not currently pay a dividend.

Dividend Growth

Sight Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.39

News Sentiment

Sight Sciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Sight Sciences this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for SGHT on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Sight Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $429,157.00 in company stock.

Percentage Held by Insiders

30.40% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/08/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• 38th Annual Healthcare Conference: 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:SGHT
• CIK: 1531177
• Web: www.sightsciences.com
• Phone: 877-266-1144
• Fax: N/A
• Employees: 186
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Sight Sciences: $9.63
• High Price Target: $14.00
• Low Price Target: $8.00
• Potential Upside/Downside: -4.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.43 million
• Net Margins: -32.13%
• Pretax Margin: -32.06%
• Return on Equity: -43.91%
• Return on Assets: -22.20%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 5.04
• Quick Ratio: 4.72

Sales & Book Value

• Annual Sales: $77.36 million
• Price / Sales: 7.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.21 per share
• Price / Book: 8.33

Miscellaneous

• Outstanding Shares: 55,580,000
• Free Float: 38,683,000
• Market Cap: $560.25 million
• Optionable: Optionable
• Beta: 2.44